FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Updates Least Burdensome Guidance

[ Price : $8.95]

Attorney Adrienne Lenz reviews new FDA guidance on the least burdensome requirement for medical device deficiency letter.

Panel Backs Sparks Gene Therapy for Vision Loss

[ Price : $8.95]

FDA's Cellular, Tissue and Gene Therapies Advisory Committee votes unanimously (16 to 0) to recommend approval for a Spark Therape...

Cranial Motion Measurement Devices Require 510(k): Correction

[ Price : $8.95]

Federal Register notice: FDA corrects a final order entitled Medical Devices; Neurological Devices; Classification of Cranial Moti...

PDUFA e-Submission and Data Standards Public Meeting

[ Price : $8.95]

Federal Register notice: FDA announces a 3/21/2018 public meeting on Prescription Drug User Fee Act of 2017; Electronic Submission...

Reviewers Cite Rhopressa Efficacy

[ Price : $8.95]

FDA medical reviewers say Aeries Rhopressa is effective in lowering eye pressure in some patients.

FDA Denies Without Comment AZ Falsodex Petition

[ Price : $8.95]

FDA denies an AstraZeneca petition asking that the agency rule on specific aspects of a 505(b)(2) NDA referencing Falsodex IM inje...

Drug Safety Data Threat Growing: PwC Report

[ Price : $8.95]

The PriceWaterhouseCoopers Health Research Institute says that drug companies face a growing threat from FDA changes to the collec...

PDUFA 6 User Fees Explained

[ Price : $8.95]

FDA issues a draft guidance explaining the user fee structures and types of fees under the PDUFA 6 reauthorization.

Draft Abbreviated Approval Pathway Guidance

[ Price : $8.95]

FDA publishes a draft guidance to help sponsors choose the appropriate abbreviated approval pathway and understand what data and i...

Merck Scraps NDA Filing for Cholesterol Drug

[ Price : $8.95]

Merck says it will not seek FDA regulatory approval for anacetrapib, an investigational cholesteryl ester transfer protein inhibit...